Awakn Life Sciences

MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
There Could Be More Hope For Alcohol Addicts As This Company Enters U.S. Addiction Treatment And Relapse Prevention Market
Sponsored
Awakn Life Sciences Receives Funding From UK Government To Identify Most Efficient Go-To-Market Pathway For Proprietary Ketamine-Assisted Therapy
Sponsored
There Could Be More Hope For Alcohol Addicts As This Company Enters U.S. Addiction Treatment And Relapse Prevention Market
Sponsored
Awakn Life Sciences Receives Funding From UK Government To Identify Most Efficient Go-To-Market Pathway For Proprietary Ketamine-Assisted Therapy
Sponsored
Awakn Life Sciences Files Patent For Exclusive Rights To Use Ketamine For Treating Behavioral Addictions
Sponsored
Awakn Life Sciences Reports Completing World's First Ketamine Study For A Range Of Behavioral Addictions
Sponsored

Awakn Life Sciences Recent News

Awakn Life Sciences Seeks To Treat Addictions: Gambling, Binge Eating And Compulsive Sexual Behavior
Awakn Life Sciences (OTC: AWKNF) is not only going after alcoholism but also binge eating disorder, compulsive sexual behavior and even Internet gaming disorder.
EXCLUSIVE: This Company Hopes to Take an Innovative Approach To Treat Addiction
Photo by Myriam Zilles on Unsplash
Sponsored
Psyched: Investment Banks Bullish On Atai Life Sciences, Wesana's $17M Purchase Of PsyTech, Creso Pharma Acquires Halucenex
A number of financial firms and investment banks initiated coverage of Atai Life Sciences (NASDAQ: ATAI) last week.
UK's Awakn Life Sciences Launches Ketamine Research Program For Alcohol And Gambling Addiction
Awakn Life Sciences Corp. (NEO: AWKN) has officially announced the launch of a research program studying the use of ketamine in substance abuse disorder and behavioral addictions.
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential of 5-MeO-DMT for the treatment of psychiatric and neurological disorders, is now listing its stock on the Nasdaq under the symbol “GHRS.” 
Awakn Life Sciences: Tackling Britain's Addiction Problems With MDMA and Ketamine
Awakn Life Sciences Corp. (NEO: AWKN), a biotech company that develops psychedelics treatments for addiction, began trading on the NEO exchange last week.
Psyched: German Government Funds Psilocybin Study, Field Trip Opens Psilocybin Clinic
Global Developments in Germany, Canada and Brazil Germany has approved a large phase 2b study on psilocybin for treatment-resistant depression.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved